Global Digital Breast Tomosynthesis Market Outlook
Revenue, 2024
Forecast, 2034
CAGR, 2024 - 2034
DBM refers to state of the art technology that produces images of different layers of breast tissue to offer in depth information to radiologists. An evident shift in the DBM sector is its growing presence in institutions worldwide because of its proven effectiveness, in enhancing the detection rates of cancer.
Market Key Insights
- The Digital Breast Tomosynthesis market is projected to grow from $3.2 billion in 2024 to $10.5 billion in 2034. This represents a CAGR of 12.7%, reflecting rising demand across Early Detection of Breast Cancer, Routine Screening and Follow-up Evaluation after Cancer Treatment.
Hologic, GE Healthcare, and Fujifilm Holdings Corporation are among the leading players in this market, shaping its competitive landscape.
- U.S. and Germany are the top markets within the Digital Breast Tomosynthesis market and are expected to observe the growth CAGR of 11.4% to 15.2% between 2024 and 2030.
- Emerging markets including India, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 8.9% to 13.3%.
Transition like Emerging AI Integration is expected to add $1.0 billion to the Digital Breast Tomosynthesis market growth by 2030
- The Digital Breast Tomosynthesis market is set to add $7.4 billion between 2024 and 2034, with manufacturer targeting Diagnostic Centers & Others End-User projected to gain a larger market share.
- With
rising prevalence of breast cancer, and
technological advancements in medical imaging, Digital Breast Tomosynthesis market to expand 231% between 2024 and 2034.
Opportunities in the Digital Breast Tomosynthesis
The field of healthcare has been gaining attention lately with a focus, on delivering individualized patient care.
Growth Opportunities in North America and Europe
North America Outlook
In North America the market for Digital Breast Tomosynthesis is fiercely competitive and well developed because of the embrace of cutting edge medical technologies and the presence of top manufacturers in the region. The higher occurrence of breast cancer and investments in healthcare infrastructure also play a role in driving market demand. The availability of insurance coverage, for DBT examinations additionally fuels growth in this market.
Europe Outlook
In Europe's DBT market growth is fueled by the growing focus on detecting breast cancer and the strong healthcare system in the region benefiting from technological progress in DBT and active participation of major players. Nevertheless challenges may arise due to the costs of DBT equipment and the need for trained experts. Nonetheless there are prospects in markets, within Europe.
Market Dynamics and Supply Chain
Driver: Rising Prevalence of Breast Cancer, and Increase in Healthcare Spending
Advancements in medical imaging technology have also continually pushed the DBT market ahead well The incorporation of AI, into DBT has also enhanced its effectiveness even more by aiding in accurate detection and diagnosis.
Restraint: High Installation and Maintenance Cost
Opportunity: Integration of AI into DBT and Extension to Rural and Remote Areas
Digital Breast Tomosynthesis has greatly benefited the healthcare sector by offering 3D mammographic images that enhance diagnostic capabilities significantly. Nevertheless there exists an untapped market in rural and remote areas across many countries, where access, to cutting edge medical technology remains scarce. Introducing DBT to these underserved regions can address a pressing demand making diagnostic services more reachable and notably enhancing results.
Challenge: Regulatory Hurdles
Supply Chain Landscape
Mitsubishi Chemical
DuPont
Hitachi Metals
Samsung
GE Healthcare
Siemens Healthineers
Hospitals
Diagnostic Centers
Breast Cancer Screening Programs
Mitsubishi Chemical
DuPont
Hitachi Metals
Samsung
GE Healthcare
Siemens Healthineers
Hospitals
Diagnostic Centers
Breast Cancer Screening Programs
Applications of Digital Breast Tomosynthesis in Early Detection of Cancer, Routine Screening & Follow-up Evaluation after Cancer Treatment
Digital Breast Tomosynthesis is mainly utilized for detecting breast cancer at a stage using its three dimensional images that offer detailed layers of the breast structure to improve the precision of cancer detection and reduce false positive diagnoses significantly. The leading players in the market, like Hologic and GE Healthcare rely heavily on this technology to deliver diagnostic services.
In breast screening procedures DBT plays a crucial role by offering a more comprehensive view compared to conventional mammography. Its enhanced capabilities enable the detection of a range of breast conditions and tumors. Siemens Healthineers and Fujifilm are leading providers of this service.
DBTs are also used in assessments following cancer therapy providing detailed imaging that enables medical professionals to track the impact of treatment and identify potential relapses early on in the process of recovery post cancer treatment phase transition periods companies, like Canon Medical Systems and Planmed play significant roles in utilizing DBTs for this critical aspect of cancer care.
Recent Developments
Siemens Healthineers has introduced a Digital Breast Tomosynthesis system that comes with advanced AI features aimed at enhancing detection accuracy and minimizing patient discomfort.
The new3D mammography scanner from Hologic Inc has been given the light by the FDA; its set to revolutionize image clarity and scanning efficiency, in Digital Breast Tomosynthesis.
GE Healthcare revealed their intentions to expand with their Digital Breast Tomosynthesis offerings following the completion of successful trials, in North America and Europe.
DBT also referred to as 3D mammographys experiencing a surge in popularity and acceptance in current market trends with its advanced features proving invaluable in detecting and treating breast cancer early to significantly enhance patient outcomes. Due, to the recognized potential of DBT technology many healthcare organizations are reallocating their resources and investments to embrace this approach.